Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 50 to 75 years of age~2. Scheduled THA~3. ASA Score ≤ 3~4. Signed written informed consent~Exclusion Criteria:~1. Muscle diseases~2. Severe neurological diseases~3. Opioid long term medication~4. Pain chronification \> stadium II of Gerbershagen~5. Immunosuppression due to illness or medication~6. Ankylosing spondylitis~7. History of ectopic bone formation of any localisation~8. Exclusion criteria for MRI (pace maker, defibrillator, ferromagnetic intracerebral clips)~9. Uncontrolled hypertension (defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 200 mmHg during screening)~10. Life-threatening ventricular arrhythmia or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged~11. ST segment elevation myocardial infarction and/or TIA/CVA within three (3) months prior to enrollment. Subjects with severe congestive heart failure symptoms (i.e. NYHA Stage IV)~12. Subject has malignancy undergoing treatment including chemotherapy, radiotherapy or immunotherapy~13. Body Mass Index (BMI) of 35 Kg/m2 or greater~14. Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the cell production process~15. Known HIV, syphilis at time of screening~16. Known active Hepatitis B, or Hepatitis C infection at the time of screening~17. Pregnant or breast-feeding women or women of childbearing potential not protected by an effective contraceptive method of birth control (defined as pearl index \< 1)~18. In the opinion of the investigator, the subject is unsuitable for cellular therapy~19. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s)~20. Subjects who are legally detained in an official institute

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 150M PLX-PAD (Type: EXPERIMENTAL): Single course, multiple IM injections
- 300M PLX-PAD (Type: EXPERIMENTAL): Single course, multiple IM injections
- Placebo (Type: PLACEBO_COMPARATOR): Single course, multiple IM injections

Based on this trial design, predict the completion outcome and termination type (if applicable).